10-QPeriod: Q1 FY2024

CENTENE CORP Quarterly Report for Q1 Ended Mar 31, 2024

Filed April 26, 2024For Securities:CNC

Summary

Centene Corporation (CNC) reported its first quarter 2024 financial results, showcasing solid revenue growth driven by its Commercial Marketplace business. Total revenues reached $40.4 billion, a 4% increase year-over-year, primarily fueled by a 41% membership surge in its Ambetter Health product. Despite overall revenue growth, the company experienced a slight decrease in managed care membership and a nominal increase in the health benefits ratio (HBR) to 87.1%. Net earnings attributable to Centene Corporation were $1.16 billion, or $2.16 per diluted share, an increase from the prior year. The company also highlighted progress in divesting non-core international assets and expanding its Medicaid footprint in various states. Operationally, Centene is navigating the complex landscape of Medicaid redeterminations, which have impacted membership but are expected to see most states conclude by the second quarter of 2024. The company is strategically positioned to capture members transitioning from Medicaid to the Health Insurance Marketplace. While Medicare Advantage revenue saw a decline due to lower Star quality ratings, the Medicare Prescription Drug Plan (PDP) membership saw significant growth. Centene's proactive approach to market changes, ongoing value creation plan, and focus on operational efficiency provide a stable outlook despite regulatory shifts.

Financial Statements
Beta
Revenue$40.41B
Cost of Revenue$669.00M
Gross Profit$4.74B
SG&A Expenses$3.22B
Operating Expenses$39.30B
Operating Income$1.11B
Interest Expense$178.00M
Net Income$1.16B
EPS (Basic)$2.17
EPS (Diluted)$2.16
Shares Outstanding (Basic)535.11M
Shares Outstanding (Diluted)538.06M

Key Highlights

  • 1Total revenues grew 4% to $40.4 billion, driven by the Commercial Marketplace business, which saw 41% membership growth.
  • 2Net earnings attributable to Centene Corporation were $1.16 billion ($2.16 per diluted share), an increase from $1.13 billion ($2.04 per diluted share) in Q1 2023.
  • 3Health Benefits Ratio (HBR) slightly increased to 87.1% from 87.0% year-over-year, influenced by Medicare Advantage revenue impacts and higher Medicaid acuity.
  • 4Managed care membership remained stable at 28.4 million, a slight decrease of 33,000 members year-over-year.
  • 5The company completed divestitures of non-core international assets (Operose Health and Circle Health).
  • 6Medicaid membership declined due to ongoing eligibility redeterminations, but the company is well-positioned to transition members to its Commercial Marketplace products.
  • 7Medicare Prescription Drug Plan (PDP) membership increased by 44% year-over-year.

Frequently Asked Questions

Centene Corporation reported total revenues of $40.4 billion, a 4% increase year-over-year, driven by growth in its Commercial Marketplace business. Net earnings attributable to Centene Corporation were $1.16 billion, or $2.16 per diluted share, representing an increase from the prior year's first quarter.

Centene is actively engaging with members to confirm their Medicaid eligibility or help them find alternative coverage. The company believes it is well-positioned to transition members to its Ambetter Health Marketplace product as Medicaid redeterminations continue, with most states expected to conclude by the second quarter of 2024.

While Medicare Advantage revenue saw a decrease due to the impact of lower Star quality ratings, the Medicare Prescription Drug Plan (PDP) membership experienced significant growth, increasing by 44% year-over-year. The company has a multi-year plan to improve quality across its Medicare Advantage contracts.

Yes, Centene has completed the divestitures of its international operations, Operose Health Group in December 2023 and Circle Health in January 2024. The company continues to focus on optimizing its portfolio.